

PRESS RELEASE

15 August 2024 16:44:00 CEST

PATENT FOR INFANT BACTERIAL THERAPEUTICS HAS BEEN APPROVED IN THE USA

Infant Bacterial Therapeutics AB (IBT) announces today that it has been granted a Notice of Allowance from the US Patent and Trademark Office (USPTO), meaning that IBT's patent application has been approved. The patent pertains to the drug candidate IBP-9414, which has been developed by IBT for the prevention of Necrotizing Enterocolitis (NEC) and to improve the nutritional intake and development of premature infants.

The invention encompasses a unique method of activating freeze-dried bacteria. The patent reinforces the existing intellectual property protection for IBT's drug candidate IBP-9414. IBT has been granted orphan drug status in both the USA and the EU. Furthermore, IBP-9414 is a biologic medicine which further strengthens protection through data exclusivity in the USA and EU.

The plan is to launch IBP-9414 on the US market as soon as market authorization is obtained. The phase III clinical study was completed in July 2024, and the study results are expected this quarter.

CEO Staffan Strömberg comments, *"The intellectual property protection for IBP-9414 was already strong before this US patent was approved, as the project had already been granted Orphan Drug Status and is a biologic. The US market is the largest and most important. Being able to strengthen IP protection and additionally extend its duration is great news."*

This information is information that Infant Bacterial Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-15 16:44 CEST.

Attachments

[Patent for Infant Bacterial Therapeutics has been approved in the USA](#)